Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
66 hedge funds and large institutions have $63.3M invested in Stemline Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 17 reducing their positions, and 9 closing their positions.
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
6% more funds holding
Funds holding: 62 → 66 (+4)
34% less capital invested
Capital invested by funds: $96.3M → $63.3M (-$33M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.44M |
| 2 |
RA
Royce & Associates
New York
|
+$983K |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$945K |
| 4 |
Millennium Management
New York
|
+$889K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$882K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.97M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.2M |
| 3 |
Goldman Sachs
New York
|
-$3.65M |
| 4 |
VM
VHCP Management
New York
|
-$2.56M |
| 5 |
OPPM
Opus Point Partners Management
New York
|
-$662K |
STML Hedge Fund Activity: Q4 2015 in Review
66 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2015, worth a combined $63.3M — down 34% from $96.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new STML positions and 9 closed out — a net gain of 4 holders — while 24 added to existing stakes and 17 trimmed.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $1.44M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $5.97M sold.
- 66 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2015, up from 62 in Q3 2015.
- Funds reported $63.3M of Stemline Therapeutics, Inc. stock for Q4 2015, down 34% quarter-over-quarter.
- 13 funds opened new Stemline Therapeutics, Inc. positions in Q4 2015 and 9 closed out, a net change of +4 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q4 2015 was Oxford Asset Management, an estimated $1.44M added.
- The largest Stemline Therapeutics, Inc. seller in Q4 2015 was Farallon Capital Management, an estimated $5.97M sold.
Based on aggregated 13F filings for Q4 2015.